Krebs Biochemicals & Industries Ltd Q3 FY26 – ₹219 Cr Debt, Negative Net Worth, One Shutdown Plant & Yet Another “Turnaround” Story
1. At a Glance
Let’s not sugarcoat this. Krebs Biochemicals & Industries Ltd is the kind of stock that tests your faith, patience, and Excel skills — all at once.
Market cap sitting at ₹123 Cr, stock price at ₹57, down 43% in one year, with negative net worth, ROCE at -30%, OPM at -43%, and debt ballooned to ₹219 Cr. If numbers could scream, these would be asking for oxygen.
Q3 FY26 revenue came in at ₹7.27 Cr, down 36.6% YoY, while losses narrowed sequentially (PAT -₹3.13 Cr, QoQ improvement of ~60%). That’s like celebrating because the ship is sinking slightly slower.
Promoters still hold 72.74%, with Ipca Laboratories owning 49.65% — which is the single biggest reason this company is still discussed seriously and not as a pure case study in financial distress.
But here’s the twist: one plant shut down, pollution board drama, decade-long losses… and still, people whisper the word “revival”. Let’s open the file properly. 🕵️♂️
2. Introduction
Krebs Biochemicals was incorporated in 1991, and for most of its listed life, it has behaved less like an API company and more like a financial endurance test.
The company manufactures Active Pharmaceutical Ingredients (APIs) and steroid intermediates — a space where margins should be healthy if scale, compliance, and execution cooperate. Unfortunately, Krebs has spent the last decade fighting everything except competitors:
erratic operations
regulatory shutdowns
mounting debt
continuous losses
negative reserves that look like a horror movie sequel
Yet, unlike many microcap pharma disasters, Krebs has one unusual plot armour: Ipca Laboratories. Ipca didn’t just buy shares — it infused ₹100 Cr via preference shares and converted 19.4 lakh warrants at ₹86/share, signaling long-term intent, not trading interest.
So the story is not “Is Krebs doing well?” The real question is: Can Ipca drag Krebs back from the ICU?
3. Business Model – WTF Do They Even Do?
Krebs is an API and intermediate manufacturer, focused primarily on:
This is not a diversified API basket — this is dependency risk wearing a lab coat.
Upcoming products like Amlodipine, Cetirizine, Telmisartan, Orlistat, Serratiopeptidase sound great on paper, but until volumes show up in quarterly revenue, they remain PowerPoint molecules.
Manufacturing units are located in Regadichelika and Kothapalli (Andhra Pradesh) — one of which (Vizag unit) has been shut down multiple times by APPCB.
Let’s pause here: 👉 What is an API company without uninterrupted manufacturing?
4. Financials Overview
Quarterly Comparison Table (₹ Cr)
Metric
Latest Qtr (Dec’25)
YoY Qtr (Dec’24)
Prev Qtr (Sep’25)
YoY %
QoQ %
Revenue
7.27
11.47
4.17
-36.6%
+74.3%
EBITDA
0.30
-4.71
-2.80
NA
NA
PAT
-3.13
-7.74
-6.14
+59.6%
+49.0%
EPS (₹)
-1.45
-3.59
-2.85
+59.6%
+49.1%
Annualised EPS (Q3 rule) Average of Q1, Q2, Q3 EPS × 4 ≈ still deeply negative
Translation: losses are shrinking, but profitability is still on vacation.
5. Valuation Discussion – Fair Value Range
Let’s be brutally honest — traditional valuation doesn’t work here, but for educational purposes, let’s still walk through it.
P/E Method
EPS (TTM): -₹10.6
P/E meaningless when earnings are negative
EV/EBITDA
Enterprise Value: ₹344 Cr
EBITDA (TTM): Negative Again, meaningless
DCF
DCF requires predictable cash flows. Krebs currently produces predictable losses.
